Diagnostics

Pancreatic cancer is the 12th most common cancer worldwide but has the sixth-highest death rate. Early detection is crucial because survival drops sharply with disease progression: localized cancer has a 44% five-year survival rate, compared with 16% for regional disease and only 3% for distant disease. Unfortunately, fewer than one in seven cases are diagnosed […]

A new study from Mass General Brigham published in the Journal of the National Cancer Institute reports a major advance in early detection of HPV-linked head and neck cancer. The new blood test, called HPV-DeepSeek, uses whole-genome sequencing to find tiny fragments of HPV DNA in the bloodstream. It was able to detect cancer up to

Gastric cancer (GC) is a leading cause of cancer death globally. Early diagnosis is critical, as the five-year survival rate drops from up to 99% for early-stage GC (EGC) to under 30% for advanced stages. While standard endoscopy screening has lowered mortality in some countries, it is generally too expensive and invasive for large-scale public

A study used non-interventional, prospectively collected plasma from the ARIC cohort to assess a multi-cancer early detection (MCED) strategy using circulating tumor DNA (ctDNA). This unique design allowed for the observation of cancer’s natural progression. In Phase I, analyzing “Early plasma samples” (collected ≤6 months before diagnosis) from 26 cancer cases and 26 controls, ctDNA

Early detection of kidney cancer is advancing rapidly through liquid biopsies and AI-enhanced diagnostics, shifting from incidental discoveries to proactive screening. Liquid biopsies analyze tumor-derived genetic material or proteins in blood and urine. Techniques like cfDNA fragmentomics, combined with machine learning, can accurately distinguish malignant from benign lesions. Biomarkers such as KIM-1, AQP1, and adipophilin are

Recent advances in ovarian cancer detection are focusing on three main areas: Liquid Biopsy: Using non-invasive blood tests to detect circulating tumor DNA (ctDNA) and other biomarkers like microRNAs. AI and Machine Learning: Applying AI to analyze medical images (ultrasound, CT scans) and integrate various data sources to improve diagnostic accuracy and identify subtle patterns. New Biomarkers: Developing

New technologies are transforming early ovarian cancer detection, aiming to identify this “silent killer” at more treatable stages. AI-powered tools like Ovatools combine biomarkers such as CA125 with patient data to generate personalized risk scores, improving early diagnosis. Machine learning is also being used to analyze metabolic patterns in blood, detecting subtle cancer signals with

New technologies are advancing early pancreatic cancer detection using highly sensitive blood tests and AI. Magnetic nanosensors can detect tumor-released proteases from just a small blood sample in under an hour at extremely low cost. When combined with CA 19-9, early-stage detection accuracy reaches about 85%. AI-powered DNA fragment analysis also shows strong results, with

Liquid biopsy is transforming lymphoma diagnosis and monitoring by analyzing circulating tumor DNA (ctDNA) from blood instead of traditional tissue biopsies. This approach enables early detection and helps track treatment response. For example, EBV DNA can be detected in T-cell lymphoma, and AI can enhance monitoring in follicular lymphoma, offering more precise insights into disease

AI and liquid biopsy technologies are transforming cancer detection, diagnosis, and treatment planning. Advanced AI algorithms are now capable of analyzing biopsy slides to identify microscopic tumor features that may be overlooked by human pathologists. For example, the DeepHRD tool evaluates standard slides to detect specific genetic deficiencies, guiding personalized treatment decisions. AI is also